Literature DB >> 2222181

Reoperative surgery for the morbidly obese. A university experience.

J A Cates1, E J Drenick, M Z Abedin, J E Doty, K D Saunders, J J Roslyn.   

Abstract

Patients who undergo surgery for morbid obesity are often subjected to reoperation for a wide array of indications. To evaluate outcome following revisional procedures, we reviewed the records of 32 such patients treated at UCLA between April 1986 and May 1989. Twenty-five women (78%) and 7 men (22%) with a mean age of 44 years underwent 76 reoperations (2.4 per patient) for complications of prior obesity surgery. Indications for initial surgical revision consisted primarily of metabolic derangements (12 patients) and weight-related problems (11 patients). In contrast, indications for the patients' final surgical procedure were commonly for bowel obstruction (41%), intra-abdominal sepsis (12%), and gastrointestinal bleeding (6%). Following initial revision, 23 patients (71.8%) required further surgery for major complications and four patients died (12.5%). While initial revisions are frequently indicated for metabolic problems, final reoperations are more frequently undertaken for urgent, life-threatening complications. Revisional procedures for morbid obesity should be carefully considered, and the potential for major complications and/or death should be weighted heavily against proposed benefits.

Entities:  

Mesh:

Year:  1990        PMID: 2222181     DOI: 10.1001/archsurg.1990.01410220184026

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  13 in total

1.  SAGES guideline for clinical application of laparoscopic bariatric surgery.

Authors: 
Journal:  Surg Endosc       Date:  2008-10       Impact factor: 4.584

2.  Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery.

Authors:  Edward H Livingston; Sergio Huerta; Denice Arthur; Scott Lee; Scott De Shields; David Heber
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  Endoscopic repair of small symptomatic gastrogastric fistulas after gastric bypass surgery: a single center experience.

Authors:  Atul Bhardwaj; Robert N Cooney; Andrew Wehrman; Ann M Rogers; Abraham Mathew
Journal:  Obes Surg       Date:  2010-08       Impact factor: 4.129

4.  Laparoscopic gastric bypass as a reoperative bariatric surgery for failed open restrictive procedures.

Authors:  J de Csepel; R Nahouraii; M Gagner
Journal:  Surg Endosc       Date:  2001-02-06       Impact factor: 4.584

5.  Endoscopic management of eroded prosthesis in vertical banded gastroplasty patients.

Authors:  Shahzeer Karmali; Brad Snyder; Erik B Wilson; Matthew D Timberlake; Vadim Sherman
Journal:  Surg Endosc       Date:  2009-06-11       Impact factor: 4.584

6.  Reoperative bariatric surgery. Lessons learned to improve patient selection and results.

Authors:  K E Behrns; C D Smith; K A Kelly; M G Sarr
Journal:  Ann Surg       Date:  1993-11       Impact factor: 12.969

7.  Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity.

Authors:  H J Sugerman; J M Kellum; E J DeMaria
Journal:  J Gastrointest Surg       Date:  1997 Nov-Dec       Impact factor: 3.452

8.  Treatment of gastric leaks with coated self-expanding stents after sleeve gastrectomy.

Authors:  Carlos Serra; Aniceto Baltasar; Luis Andreo; Nieves Pérez; Rafael Bou; Marcelo Bengochea; Juan José Chisbert
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

9.  Disappointing results with a 5 cm calibrating device for laparoscopic vertical banded gastroplasty.

Authors:  Gitana Scozzari; Mauro Toppino; Gisella Bonnet; Mario Morino
Journal:  Surg Endosc       Date:  2007-08-18       Impact factor: 4.584

10.  Conversion of vertical banded gastroplasty to Roux-en-Y gastric bypass results in restoration of the positive effect on weight loss and co-morbidities: evaluation of 101 patients.

Authors:  Ruben Schouten; Francois M H van Dielen; Wim G van Gemert; Jan Willem M Greve
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.